FDA asks for removal of the suicidal ideation warning, stranding a generation of tirzepatide side-effect pages
FDA has approved removing the suicidal ideation warning from Zepbound's label while adding intestinal obstruction and fecal impaction language, changing what patients read in the Medication Guide.
The Food and Drug Administration approved a labeling supplement for Zepbound (tirzepatide) that deletes the drug's suicidal ideation warning and, at the same time, adds new language about severe gastrointestinal problems including intestinal obstruction and fecal impaction [1].
According to the agency's supplement approval letter to Eli Lilly and Company, FDA issued a supplement request letter on January 13, 2026, asking for "the removal of information regarding suicidal ideation from the Zepbound label" [1]. The approved changes strike subsection 5.9, "Suicidal Ideation and Behavior," from the Warnings and Precautions section of the prescribing information, with corresponding updates to the Highlights, Table of Contents, Section 6, Section 17 and the Recent Major Changes section [1]. The phrase "depression or thoughts of suicide" is also removed from the possible side effects section of the Medication Guide — the handout pharmacies include with the prescription [1].
That warning traces back to a safety review FDA opened years earlier. The letter refers to a Notification of Newly Identified Safety Signal dated July 21, 2023, in which FDA told Lilly it was evaluating a suicidal ideation signal for the whole glucagon-like peptide-1 receptor agonist class, "of which Zepbound is a member" [1]. The approval letter does not include the data or analysis behind the decision to remove the language, and it does not explain what FDA concluded about the signal [1].
A second change points the other direction
The same supplement adds safety information about the gut. FDA notified Lilly on April 28, 2025, that it was evaluating a newly identified safety signal for intestinal obstruction and fecal impaction across the GLP-1 receptor agonist class, and issued a supplement request letter on October 14, 2025, to update labeling [1]. Lilly submitted the supplement on November 14, 2025 [1].
As approved, Section 5 Warnings and Precautions now states, under "Severe Gastrointestinal Adverse Reactions," that "Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists" [1]. Section 6, under Postmarketing Experience, adds "intestinal obstruction, severe constipation including fecal impaction" [1]. FDA said the suicidal ideation changes were folded into this review "rather than in a separate supplement" [1].
The letter covers Zepbound injection and the Zepbound KwikPen [1]. It does not address any other product, so what happened to the labels of other GLP-1 medicines — including semaglutide products or the tirzepatide diabetes brand Mounjaro — is not established by this document. The letter was signed by Monika Houstoun, Pharm.D., M.P.H., deputy director for safety in FDA's Division of Diabetes, Lipid Disorders, and Obesity [1]. The electronic signature on the document is dated February 25, 2026, while the request letter it describes is dated January 13, 2026; the letter itself says the approval is effective "on the date of this letter" [1].
Why it matters for patients
The Medication Guide is the plain-language document most patients actually read. Removing "depression or thoughts of suicide" from its side effects list means new Zepbound packages and updated online labeling will no longer list that as a possible effect [1]. People who started the drug earlier may have a printed guide at home that still includes it.
It also means a large share of consumer articles, pharmacy printouts and side-effect summaries describing a Zepbound suicidal ideation warning now describe a label that no longer exists. The approval letter requires Lilly to promptly revise "all promotional materials that include representations about your drug product" to be consistent with the approved changes, and to submit a statement of intent to comply within 7 days of receiving the letter [1]. That obligation applies to the manufacturer, not to third-party websites.
The added gastrointestinal language works the other way: the label now names intestinal obstruction and severe constipation including fecal impaction as postmarketing reports [1]. Postmarketing reports are events reported after approval; the letter does not give rates or say how often these occur [1].
What happens next
Lilly had 14 days from the date of the letter to submit the structured product labeling, which FDA says "will be accessible from publicly available labeling repositories" [1]. The company also had 14 days to amend pending supplemental applications with labeling changes [1]. Whether FDA takes similar action on other GLP-1 products is not addressed in this document.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.